观点：微小RNA——分子癌症治疗的新潮流。
Opinion: miRNAs - The new wave of molecular cancer therapeutics.
作者信息
Lopez-Bertoni Hernando, Laterra John
机构信息
Hugo W. Moser Research Institute at Kennedy Krieger, 707N. Broadway, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 600N. Wolfe Street, Baltimore, MD 21287, USA.
Hugo W. Moser Research Institute at Kennedy Krieger, 707N. Broadway, Baltimore, MD 21205, USA; Department of Neurology, Johns Hopkins School of Medicine, 600N. Wolfe Street, Baltimore, MD 21287, USA; Department of Neuroscience, Johns Hopkins School of Medicine, 600N. Wolfe Street, Baltimore, MD 21287, USA; Department of Oncology, Johns Hopkins School of Medicine, 600N. Wolfe Street, Baltimore, MD 21287, USA.
出版信息
Transl Oncol. 2021 Jun;14(6):101064. doi: 10.1016/j.tranon.2021.101064. Epub 2021 Mar 12.
Cutting-edge advances in nanomedicine and the recent approval of two siRNA-based therapeutics by the Food and Drug Administration (FDA) has rekindled the interest in RNA interference (RNAi) as vehicles for the development of novel cancer therapeutics. In this perspective, we will briefly discuss how miRNAs are becoming the next-generation RNAi therapeutic, the advances in delivery vehicles for in vivo miRNA delivery, and where miRNA technology stands in terms of clinical translation.
纳米医学的前沿进展以及美国食品药品监督管理局（FDA）最近批准的两种基于小干扰RNA（siRNA）的疗法，重新激发了人们对RNA干扰（RNAi）作为新型癌症治疗药物开发载体的兴趣。从这个角度来看，我们将简要讨论微小RNA（miRNA）如何成为下一代RNAi疗法、用于体内miRNA递送的载体的进展，以及miRNA技术在临床转化方面的现状。
Zotero 插件